Ongoing clinical trials in metastatic uveal melanoma
| Therapy | Mechanism of action | Phase | Identifier | Trial status |
|---|---|---|---|---|
| Selumetinib+paclitaxel | MEK1/2 inhibitor+chemotherapy | II | EudraCT: 2014-004437-22 | Recruiting |
| Trametinib+GSK2141795 | MEK inhibitor+AKT inhibitor | II | NCT01979523 | Recruiting |
| Binimetinib+AEB071 | MEK inhibitor+PKC inhibitor | I/II | NCT01801358 | Recruitment held |
| Cabozantinib | MET inhibitor | II | NCT01835145 | Recruiting |
| Vorinostat | Histone deacetylase inhibitor | II | NCT01587352 | Recruiting |
| Sorafenib | Multi-kinase inhibitor | II | NCT01377025 | Recruitment complete |
| Ganetespib | HSP90 inhibitor | II | NCT01200238 | Recruitment held |
| Adoptive T-cell transfer | Tumour-infiltrating lymphocytes | II | NCT01814046 | Recruiting |
| AEB071+BYL719 | PKC inhibitor+PI3K inhibitor | Ib | NCT02273219 | Recruiting |
| AEB071 | PKC inhibitor | I | NCT01430416 | Recruitment complete |
| Pembrolizumab | Anti-PD-1 | II | NCT02359851 | Recruiting |
HSP90, heat shock protein 90; PD-1, programmed cell death 1; PKC, protein kinase C.